Stimvia Expands Scientific Advisory Board and Commercial Leadership for URIS Therapy

Stimvia, a Czech medical technology company, has expanded its Scientific Advisory Board with leading urology experts from the U.S., UK, and EU to advance the global market expansion of its flagship therapy, URIS®. The company has also strengthened its commercial leadership by appointing Dr. David da Silva to lead global distribution and Alim Topdag as Director of Sales and Business Development for international markets, aiming to enhance therapy adoption and international growth.